Replies to post #160932 on Vivos Inc (RDGL)

[kayak_wench]

I dug up the April report before posting my guess of another test, that is where I learned the phase 2 testing is what goes from 100Gy to 800Gy. So you aren't remembering correctly, but wish you were!

Tumors are now being induced for Phase Two testing. These will be treated at a lower dose to quantify the dose-escalation effect. This defines the range of doses that result in the therapeutic effectiveness of a single therapy, in the range of 100 Gy to 800 Gy.

The phase 1 notes summary from March did note that

The therapeutic ratios and activity delivered to the target volume were as high as 18,000

Wish the 18,000 had a unit Hard to believe it would be 18,000 Gy, but if so that would explain why they also noted

This is unprecedentedly high, which confirms the importance of our Precision Radionuclide Therapy device.

Little wonder oncologists at some of the best cancer hospitals are supporting this product.

[Cameron12221]

I feel that they'll do the 800gy to cover all angles, but they also mentioned that these tests are for future publications so keep this in mind. More is brewing than we know.

The Phase Two 100Gy injections were completed. The focus was on treating margins of a complex tumor morphology tumor shape for future publications